RESUMEN
To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of essential hypertension in elderly patients, we studied 54 patients, mean age 67.2 +/- 4.7 years, with essential hypertension, I-II WHO class. After a two-week wash-out from previous hypotensive therapies, patients were divided, at random, into three groups and, in double-blind conditions; they were treated as follows: the first group was treated with Verapamil (V) slow-release 240 mg/die, the second group with Chlorthalidone (C) 50 mg/die and the third group with the combination of Verapamil slow-release 240 mg/die and Chlorthalidone 50 mg/die (V + C). In the first group, the therapy (V) statistically reduced (p less than 0.001) either PAS or PAD values in supine position, (respectively -13 +/- 9 mmHg and -12 +/- 4 mmHg) and PAS-PAD values in upright position (respectively -16 +/- 3 mmHg and -10 +/- 3 mmHg). In the group treated with C, a statistically significant reduction (p less than 0.001) of PAS (-12 +/- 3 mmHg in supine position and -16 +/- 3 mmHg in upright position) and of PAD (-11 +/- 5 in supine and -9 +/- 4 mmHg in upright position). In the third group, V + C treatment induced a statistically bigger reduction of PAS and PAD (p less than 0.001) than that of the other two groups either in supine (-24 +/- 3 and -21 +/- 5 mmHg, respectively) or in upright position (-26 +/- 4 and -20 +/- 5 mmHg, respectively). Three patients interrupted the therapy for scarse compliance (I-II group).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Clortalidona/uso terapéutico , Hipertensión/tratamiento farmacológico , Verapamilo/uso terapéutico , Anciano , Presión Sanguínea , Clortalidona/administración & dosificación , Ensayos Clínicos como Asunto , Preparaciones de Acción Retardada , Quimioterapia Combinada , Femenino , Frecuencia Cardíaca , Humanos , Masculino , Persona de Mediana Edad , Postura , Verapamilo/administración & dosificaciónAsunto(s)
Captopril/administración & dosificación , Hidroclorotiazida/administración & dosificación , Hipertensión/tratamiento farmacológico , Prolina/análogos & derivados , Adulto , Evaluación de Medicamentos , Quimioterapia Combinada , Ecocardiografía , Electrocardiografía , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Persona de Mediana Edad , FonocardiografíaAsunto(s)
Ácido Canrenoico/uso terapéutico , Cardiopatías/tratamiento farmacológico , Hipertensión/tratamiento farmacológico , Pregnadienos/uso terapéutico , Adulto , Evaluación de Medicamentos , Ecocardiografía , Femenino , Cardiopatías/etiología , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/complicaciones , Masculino , Persona de Mediana Edad , Contracción Miocárdica/efectos de los fármacosAsunto(s)
Enfermedad Coronaria/diagnóstico por imagen , Difosfatos , Marcapaso Artificial , Tecnecio , Anciano , Enfermedad Coronaria/diagnóstico , Femenino , Bloqueo Cardíaco/terapia , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/diagnóstico por imagen , Cintigrafía , Pirofosfato de Tecnecio Tc 99mRESUMEN
The Authors carried on a study in a group of 31 patients with acute myocardial infarction (AMI). The controled particularly the following dates: myoglobinemia (MG) with RIA and myocardial necrosis enzymes with traditional methods. Blood has been drawn from patients every 90 min, during the first 8 h of admission and every 4 h during the following 4 days. Important variations of MG have been detected in 80.6% of cases. These is an early increase in MG (within 4 h in 25.8% and within 8 h in 45.1% of cases) and normal values are reached in a time not longer the 72 h. The maximum value is reached in a shorter time than that creatine phosphokinase (CPK). We can therefore confirm that MG is a useful data in the early diagnosis of myocardial infarction in preenzymatic stage.